vaccine received regulatory approval for second Phase trials in August. Here is all you need to know about Bharat Biotech's nasal covid vaccine 1) The adenoviral intranasal vaccine BBV154 is the first of its kind Covid-19 vaccine to undergo human trials in India.
2) After getting the ethics committee's nod, the second phase of the trials will be conducted on volunteers who will be administered the two doses of the vaccine with a gap of four weeks in between.
3) According to the ministry of science and technology, the Phase 1 trial in healthy volunteers of age groups ranging from 18-60 years was well tolerated.